

## **Amendment to the Claims**

### Claims 1-39 (Canceled)

40. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, impaired coordination or balance ~~comprises~~ comprising decreased performance in a rotarod test.
41. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a spleen abnormality ~~comprises comprising~~ decreased spleen size.
42. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a spleen abnormality ~~comprises comprising~~ reduced spleen weight.
43. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a spleen abnormality ~~comprises comprising~~ reduced spleen to body weight ratio.
44. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a spleen abnormality ~~comprises comprising~~ lymphoid depletion of the spleen.
45. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a thymus abnormality ~~comprises comprising~~ reduced thymus size.
46. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a thymus abnormality ~~comprises comprising~~ reduced thymus weight.
47. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a thymus abnormality ~~comprises~~ reduced thymus to body weight ratio.
48. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a thymus abnormality ~~comprises comprising~~ lymphoid depletion in the thymus.

49. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a lymph node abnormality comprising lymphoid depletion.

50. (Currently amended) The transgenic mouse of claim 3955, wherein the mouse exhibits, relative to a wild-type control mouse, a lymph node abnormality comprising reduced lymph node size.

Claims 51-52 (Canceled)

53. (Currently amended) A transgenic mouse whose genome comprises a null allele of the endogenous mCAR2 allele~~gene; said null allele comprising exogenous DNA.~~

54. (Previously presented) The transgenic mouse of claim 53 wherein said mouse is heterozygous for said null allele.

55. (Previously presented) The transgenic mouse of claim 53 wherein said mouse is homozygous for said null allele.

56. (Currently amended) The transgenic mouse of claim 53 wherein said null allele~~exogenous DNA~~ comprises a gene encoding a selection-selectable marker.

57. (Currently amended) The transgenic mouse of claim 56 wherein said gene is a neomycin ~~resistant~~resistance gene.